MedTrace Logo

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

NCT06365541 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-04-15

No results posted yet for this study

Summary

Dialysis patients have a higher incidence of cardiovascular events and require more effective measures to delay the progression of heart failure. Many studies have shown that dapagliflozin has cardioprotective effect, but most studies focus on non-dialysis patients with eGFR more than 20ml/min/1.73m2. However, the data on patients with eGFR less than 20ml/min/1.73m2 or dialysis patients, especially peritoneal dialysis patients, is less. Exploring the efficacy and safety of Dapagliflozin in improving heart failure in dialysis patients is of great clinical significance.

Conditions

  • The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Interventions

DRUG

Dapagliflozin

oral Dapagliflozin tablets 10mg/day for 6 months

Sponsors & Collaborators

  • The People's Hospital of Gaozhou

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06365541 on ClinicalTrials.gov